At the news
? BULLISHIMPACT 8/10 8-K filed Apr 30, 2026 at 17:19 ET
Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with dementia due to Alzheimer's disease, a first-in-class treatment for a condition affecting up to 76% of Alzheimer's patients. This is a major label expansion for an already-approved drug (MDD), supported by Breakthrough Therapy designation and Priority Review, with a patent estate extending to at least 2043.
- FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on April 30, 2026.
- AUVELITY is a first-in-class treatment targeting NMDA and sigma-1 receptors for this indication.
- The sNDA was granted Breakthrough Therapy designation and evaluated under Priority Review.
- Approval supported by Phase 3 ADVANCE-1 and ACCORD-2 trials showing statistically significant improvement on primary and key secondary endpoints.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access